Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma
Shukui Qin, Masatoshi Kudo, Tim Meyer, Yuxian Bai, Yabing Guo, Zhiqiang Meng, Taroh Satoh, Donatella Marino, Eric Assenat, Songzi Li, Yaxi Chen, Frederic Boisserie, Ramil Abdrashitov, Richard S. Finn, Arndt Vogel, Andrew X. Zhu · 2023
Read Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma by Shukui Qin, Masatoshi Kudo, Tim Meyer, Yuxian Bai, Yabing Guo, Zhiqiang Meng, Taroh Satoh, Donatella Marino, Eric Assenat, Songzi Li, Yaxi Chen, Frederic Boisserie, Ramil Abdrashitov, Richard S. Finn, Arndt Vogel, Andrew X. Zhu (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10557031.txt.
Description
Shukui Qin and a large team compared tislelizumab with sorafenib as first treatment for liver cancer. Their 2023 phase 3 trial covers unresectable hepatocellular carcinoma. This cancer is a leading cause of cancer death worldwide. More first-line options are urgently needed for patients. Tislelizumab blocks the PD-1 checkpoint and had shown promise in later-line care.
The global trial randomized adults who had no prior systemic therapy. All had confirmed cancer at an intermediate or advanced stage. Liver function had to be preserved for entry. The drug was tested head to head against the standard sorafenib. Efficacy and safety were both tracked over the study. Results weigh a checkpoint drug as an opening move in liver cancer.
Catalog record
| CREATOR | Shukui Qin, Masatoshi Kudo, Tim Meyer, Yuxian Bai, Yabing Guo, Zhiqiang Meng, Taroh Satoh, Donatella Marino, Eric Assenat, Songzi Li, Yaxi Chen, Frederic Boisserie, Ramil Abdrashitov, Richard S. Finn, Arndt Vogel, Andrew X. Zhu |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |